You are here: Industry Insights > CAR-T

News List

Professor Carl June, the "Pioneer of CAR-T", Joined Bioheng Scientific Advisory Board prnasia
October 19, 2021
Nanjing Bioheng Biotech Co., Ltd (hereafter Bioheng), announced that Professor Carl June, an authoritative cancer immunologist and "Pioneer of Chimeric Antigen Receptor T (CAR-T) cells...
With Diversified CAR-T Products in Hand, CARSGEN Applied for IPO in Hong Kong, S.A.R., China to Challenge the Treatment of Solid Tumor PharmaSources/Chuxin
July 09, 2021
On June 18, CARSGEN Therapeutics, a pioneer in the field of CAR-T cell therapy, officially listed on the Hong Kong, S.A.R., China Stock Exchange, offering 94.747 million shares, priced at HK $32.80 per share, raising a net of about HK $2.94 billion.
Potential new CAR-T cell therapy for multiple myeloma firstwordpharma
June 28, 2021
Researchers at Mayo Clinic Cancer Center are studying a potential new chimeric antigen receptor-T cell therapy (CAR-T cell therapy) treatment for multiple myeloma. Their findings were published on Friday, June 24, in The Lancet.
China's first CAR-T Cell Therapy approved-Fosun Kite Axicabtagene Ciloleucel (FKC876) prnasia
June 25, 2021
On June 23, 2021, Fosun Kite Biotechnology announced its autologous CD19-directed CAR-T cell therapy Axicabtagene Ciloleucel (FKC876) (axicabtagene ciloleucel) has been approved by China National Medical Products Administration (NMPA) for the ...
CellPoint and Lonza Enter Strategic Collaboration contractpharma
June 25, 2021
CellPoint has signed an agreement with Lonza's Personalized Medicine Business Unit to employ Lonza's Cocoon Platform for clinical manufacturing of CellPoint's CAR-T cell therapies at the point-of-care, more rapidly and at lower cost.
Cancer Research UK partners with Aleta Biotherapeutics on blood cancer therapy pharmatimes
June 24, 2021
Cancer Research UK (CRUK) and biotech company Aleta Biotherapeutics have entered into a collaboration on the early phase clinical development of Aleta’s blood cancer therapy candidate ALETA-001.
Blackstone Life Sciences, Cellex Cell Professionals, and Intellia Therapeutics Launch New CAR T-Cell Company americanpharmaceuticalreview
June 23, 2021
Blackstone Life Sciences has committed $250 million towards the launch of a new autologous and allogeneic universal chimeric antigen receptor (CAR) T-cell therapy company, along with Intellia Therapeutics, Inc. and Cellex Cell Professionals GmbH.
CARsgen Therapeutics officially listing on HKEX prnasia
June 21, 2021
CARsgen Therapeutics Holdings Limited announced that the Company's Shares have been traded on the Main Board of The Stock Exchange of Hong Kong, S.A.R., China Limited under the stock code "2171.HK".
Harbour BioMed and Dana-Farber Cancer Institute Collaborate to Advance Novel Biotherapies for Cancer Treatment prnasia
June 16, 2021
Harbour BioMed announced today it has entered into a multi-year, multifaceted research collaboration agreement with Dana-Farber Cancer Institute to co-develop novel biotherapies in cancer treatment.
ProCell for Patient Project to Develop Automated Production Unit for CAR-T Cell Therapies contractpharma
June 11, 2021
Standardized and automated manufacturing aims to reduce the amount of work on producing CAR-T cells by 50 percent.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 13 14 Next page